Medtronic plc MDT recently announced three-month favorable results from an on-label, prospective, multi-center study showing meaningful pain relief using DTM SCS endurance therapy. Notably, DTM SCS ...
At Three-Months, 80% of Patients Treated with DTM SCS Reported Back Pain Reliefof at Least 50%; 63% Reported Profound Back Pain Relief of 80% or Greater1 The RCT demonstrated profound pain relief and ...
Medtronic plc (MDT) has announced statistically significant 12-month results from a large, multicenter trial (RCT) that it says further proves the superiority of DTM Spinal Cord Stimulation (SCS) in ...
Medtronic plc released initial results showing meaningful pain relief using differential target multiplexed (DTM) spinal cord stimulation (SCS) endurance therapy, a lower-energy form of its DTM SCS ...
Medtronic announced the US Food and Drug Administration (FDA) has approved revised commercial labeling for the Intellis Platform with Differential Target Multiplexed (DTM) programming for the ...
Medtronic plc today announced three-month results from a large, multicenter randomized controlled trial (RCT) showing statistically significant (p=0.0009) and superior back pain relief with ...
The high-profile medical device specialist is the proud new owner of Stimgenics. The signature product for Stimgenics, based in Illinois, is its Differential Target Multiplexed (DTM) Spinal Cord ...
A literature search was carried out for this briefing in accordance with the interim process and methods statement for medtech innovation briefings. This briefing includes the most relevant or best ...
Mumbai: Medtronic Private Limited announced the first clinical procedure in India with the Intellis spinal cord stimulation (SCS) platform. The stimulator is the world’s smallest SCS device for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback